NRG
AZN icon

Nemes Rush Group’s AstraZeneca AZN Stock Holding History

Nemes Rush Group’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-135
Closed -$24.8K – 951
2025
Q4 		$24.8K Buy
135
+83
+160% +$14.6K ﹤0.01% 435
2025
Q3 		$7.87K Sell
52
-26
-33% -$3.94K ﹤0.01% 509
2025
Q2 		$10.9K Buy
78
+27
+53% +$3.78K ﹤0.01% 464
2025
Q1 		$7.5K Sell
51
-15
-23% -$2.17K ﹤0.01% 498
2024
Q4 		$8.62K Buy
66
+16
+32% +$2.24K ﹤0.01% 486
2024
Q3 		$6.78K Hold
50
– – ﹤0.01% 437
2024
Q2 		$7.8K Sell
50
-230
-82% -$34.6K ﹤0.01% 429
2024
Q1 		$37.9K Sell
280
-1
-0.4% -$132 0.01% 315
2023
Q4 		$37.8K Buy
281
+67
+31% +$8.71K 0.01% 295
2023
Q3 		$29K Buy
214
+169
+376% +$23.1K 0.01% 303
2023
Q2 		$6.44K Buy
+45
New +$6.62K ﹤0.01% 467

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Nemes Rush Group's AZN Position: Q1 2026 in Review

Nemes Rush Group sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 135 shares — an estimated $24.8K sold.

Nemes Rush Group first reported a position in AZN in Q2 2023 and held it in 11 quarters. The position peaked at $37.9K in Q1 2024. 1,378 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Nemes Rush Group reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
  • Nemes Rush Group sold 135 AstraZeneca shares in Q1 2026, an estimated $24.8K.
  • Nemes Rush Group first reported a position in AstraZeneca in Q2 2023 and held it in 11 quarters.
  • Nemes Rush Group's AstraZeneca position peaked at $37.9K in Q1 2024.
  • 1,378 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Nemes Rush Group's 13F filing for Q1 2026, filed 21 Apr 2026.